Shengnuo Biotech announced that it recently received a “Notice Letter on the Progress of Stock Reduction” from Chuanfa Investment. From September 18 to December 10, 2025, it reduced its holdings by a total of 31478.96 million shares through centralized bidding and bulk transactions, accounting for 2.0001% of the total share capital. After the change in equity, Chuanfa Investment's shareholding fell from 110,169.95 million shares to 78689.99 million shares, and the ratio decreased from 7.0000% to 4.9999%. It is no longer a shareholder holding 5% or more of the shares. This change is due to the implementation of the holdings reduction plan, does not affect the proposed acquisition, does not affect the controlling interest, and the holdings reduction plan has not been implemented.

Shengnuo Biotech announced that it recently received a “Notice Letter on the Progress of Stock Reduction” from Chuanfa Investment. From September 18 to December 10, 2025, it reduced its holdings by a total of 31478.96 million shares through centralized bidding and bulk transactions, accounting for 2.0001% of the total share capital. After the change in equity, Chuanfa Investment's shareholding fell from 110,169.95 million shares to 78689.99 million shares, and the ratio decreased from 7.0000% to 4.9999%. It is no longer a shareholder holding 5% or more of the shares. This change is due to the implementation of the holdings reduction plan, does not affect the proposed acquisition, does not affect the controlling interest, and the holdings reduction plan has not been implemented.